Probio-M9 and Genetic Senolysis Attenuate Experimental Colitis by Targeting Inflammation-Associated Cellular Senescence

Gaopeng Li; Zhixin Zhao; Feiyan Zhao; Masakazu Ishikawa; Kensuke Kumamoto; Kiyomi Ohmichi; Ryou Ishikawa; Satoshi Yamazaki; Zhihong Sun; Lin Hai Kurahara

doi:10.1016/j.eng.2026.07.037

Engineering ›› :202607037 DOI: 10.1016/j.eng.2026.07.037

research-article

Probio-M9 and Genetic Senolysis Attenuate Experimental Colitis by Targeting Inflammation-Associated Cellular Senescence

Author information +

History +

PDF (9877KB)

Abstract

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic intestinal inflammation and limited therapeutic options. Cellular senescence contributes to persistent inflammation through the senescence-associated secretory phenotype (SASP), suggesting that modulation of senescence may represent a novel therapeutic strategy. Here, we investigated the therapeutic effects of probiotic Lacticaseibacillus rhamnosus Probio-M9 2095-8099/© 2026 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords

Cellular senescence / Inflammatory bowel disease / Gut microbiota / Probiotics / Senolysis

Cite this article

Download citation ▾

Gaopeng Li, Zhixin Zhao, Feiyan Zhao, Masakazu Ishikawa, Kensuke Kumamoto, Kiyomi Ohmichi, Ryou Ishikawa, Satoshi Yamazaki, Zhihong Sun, Lin Hai Kurahara. Probio-M9 and Genetic Senolysis Attenuate Experimental Colitis by Targeting Inflammation-Associated Cellular Senescence. Engineering 202607037 DOI:10.1016/j.eng.2026.07.037

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Kaplan GG . The global burden of inflammatory bowel disease: from 2025 to 2045. Nat Rev Gastroenterol Hepatol 2025; 22(10):708—20.

[2]	Limketkai BN, Godoy—Brewer G, Parian AM, Noorian S, Krishna M, Shah ND, et al. Dietary interventions for the treatment of inflammatory bowel diseases: an updated systematic review and meta—analysis. Clin Gastroenterol Hepatol 2023; 21(10):2508—25.

[3]	Luo X, Zhao M, Cui C, Gui M, Yang Z, Liu M . Senescence—related gene signatures in Crohn’s disease: integrating bulk and single—cell RNA sequencing analysis. Sci Rep 2025; 15(1):45269.

[4]	Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F . Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 2021; 22(2):75-95.

[5]	Sienkiewicz M, Sroka K, Binienda A, Jurk D, Fichna J . A new face of old cells: an overview about the role of senescence and telomeres in inflammatory bowel diseases. Ageing Res Rev 2023; 91:102083.

[6]	Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL . Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123(3):966-72.

[7]	Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann—Stroissnigg H, Xu M, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 2018; 36:18-28.

[8]	Derwa Y, Gracie DJ, Hamlin PJ, Ford AC . Systematic review with meta—analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 46(4):389-400.

[9]	Gout J, Perkhofer L, Morawe M, Arnold F, Ihle M, Biber S, et al. Synergistic targeting and resistance to PARP inhibition in DNA damage repair—deficient pancreatic cancer. Gut 2021; 70(4):743-60.

[10]	Kowald A, Passos JF, Kirkwood TBL . On the evolution of cellular senescence. Aging Cell 2020; 19(12):e13270.

[11]	Covre LP, De Maeyer RPH, Gomes DCO, Akbar AN . The role of senescent T cells in immunopathology. Aging Cell 2020; 19(12):e13272.

[12]	Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A . Cellular senescence: aging, cancer, and injury. Physiol Rev 2019; 99(2):1047-78.

[13]	Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y . Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest 2022; 132(15):e158450.

[14]	Jang DH, Shin JW, Shim E, Ohtani N, Jeon OH . The connection between aging, cellular senescence and gut microbiome alterations: a comprehensive review. Aging Cell 2024; 23(10):e14315.

[15]	Gao G, Shen S, Zhang T, Zhang J, Huang S, Sun Z, et al. Lacticaseibacillus rhamnosus Probio—M9 enhanced the antitumor response to anti—PD—1 therapy by modulating intestinal metabolites. EBioMedicine 2023; 91:104533.

[16]	Vallejos OP, Bueno SM, Kalergis AM . Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects. Trends Mol Med 2025; 31(8):731—42.

[17]	Zhao F, Hiraishi K, Li X, Hu Y, Kojima D, Sun Z, et al. Long—term tracking of the effects of colostrum—derived Lacticaseibacillus rhamnosus Probio—M9 on gut microbiota in mice with colitis—associated tumorigenesis. Biomedicines 2024; 12(3):531.

[18]	Zhao Z, Li G, Ohmichi K, Li X, Zhao F, Ishikawa K, et al. Lacticaseibacillus rhamnosus Probio—M9 alters the gut microbiota and mitigates pulmonary hypertension in a rat model. Nutrients 2025; 17(18):2927.

[19]	Xu H, Hiraishi K, Kurahara LH, Nakano—Narusawa Y, Li X, Hu Y, et al. Inhibitory effects of breast milk—derived Lactobacillus rhamnosus Probio—M9 on colitis—associated carcinogenesis by restoration of the gut microbiota in a mouse model. Nutrients 2021; 13(4):1143.

[20]	Zhang W, Zhang Y, Li Y, Ma D, Zhang H, Kwok LY . Lacticaseibacillus rhamnosus Probio—M9—driven mouse mammary tumor—inhibitory effect is accompanied by modulation of host gut microbiota, immunity, and serum metabolome. Nutrients 2022; 15(1):5.

[21]	Zhang J, Zhao Y, Sun Z, Sun T . Lacticaseibacillus rhamnosus Probio—M9 extends the lifespan of Caenorhabditis elegans . Commun Biol 2022; 5(1):1139.

[22]	Zheng Y, Yu Z, Zhang W, Sun T . Lactobacillus rhamnosus Probio—M9 improves the quality of life in stressed adults by gut microbiota. Foods 2021;10(10):2384.

[23]	Omori S, Wang TW, Johmura Y, Kanai T, Nakano Y, Kido T, et al. Generation of a p16 reporter mouse and its use to characterize and target p16^high cells in vivo . Cell Metab 2020; 32(5):814-28.e6.

[24]	Reyes NS, Krasilnikov M, Allen NC, Lee JY, Hyams B, Zhou M, et al. Sentinel p16^INK4a+ cells in the basement membrane form a reparative niche in the lung. Science 2022; 378(6616):192-201.

[25]	Zhao H, Liu Z, Chen H, Han M, Zhang M, Liu K, et al. Identifying specific functional roles for senescence across cell types. Cell 2024; 187(25):7314—34.

[26]	Iwasaki K, Komiya H, Kakizaki M, Miyoshi C, Abe M, Sakimura K, et al. Ablation of central serotonergic neurons decreased REM sleep and attenuated arousal response. Front Neurosci 2018; 12:535.

[27]	Friedrich M, Pohin M, Jackson M, Korsunsky I, Bullers S, Rue—Albrecht KC, et al. IL—1—driven stromal—neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med 2021; 27:1970-81.

[28]	Peck BCE, Weiser M, Lee SE, Gipson GR, Iyer VB, Sartor RB, et al. MicroRNAs classify different disease behavior phenotypes of Crohn’s disease and may have prognostic utility. Inflammatory Bowel Dis 2015; 21(9):2178-87.

[29]	Garrido—Trigo A, Corraliza AM, Veny M, Dotti I, Melón—Ardanaz E, Rill A, et al. Macrophage and neutrophil heterogeneity at single—cell spatial resolution in human inflammatory bowel disease. Nat Commun 2023; 14:4698.

[30]	Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58(12):1612—9.

[31]	Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, et al. The effect of vedolizumab (anti—α4β7 integrin) therapy on colonic mucosal gene expression in patients with ulcerative colitis. J Crohns Colitis 2018; 12(8):973-87.

[32]	Saul D, Kosinsky RL, Atkinson EJ, Doolittle ML, Zhang X, LeBrasseur NK, et al. A new gene set identifies senescent cells and predicts senescence—associated pathways across tissues. Nat Commun 2022; 13:4827.